Electromedical Technologies
Enters Phase 2 of Prototype
development on
WellnessPro
POD™
-
Efficacy and Product Integration Testing Slated for Completion
in Fall 2021
-
Upon FDA Clearance the Wellness Pro POD™
Device Could Emerge as a Leading Chronic
Pain drug-free choice to Opioids for
Mass Market Retail Customers.
SCOTTSDALE, AZ -- April 20, 2021 -- InvestorsHub NewsWire
-- Electromedical Technologies,
Inc. (OTCQB:
EMED )
(the "Company"), a pioneer in the development and manufacturing of
bioelectronic devices, including the FDA cleared
WellnessPro+Plus® is pleased to announce
that the
Company has entered into Phase 2 of prototype construction of the
new WellnessPro
POD™. The second
phase of the process features overall
efficacy
and product
integration
testing and is
slated to be
completed in the Fall
2021. Once
complete, the device will be used in a 510(k) medical device
submission with the U.S. Food & Drug
Administration (FDA). WellnessPro
POD™ is
positioned as a new, smaller, professional grade wearable device
for mass market retail customers seeking
non-opioid therapy to treat chronic pain, and has the
ability to work with the Company's
flagship
WellnessPro+Plus® device.
Chronic
and acute
pain
sufferers around the world
are actively
seeking non-opioid alternatives to treat their
conditions, especially
during the
COVID-19 pandemic, as noted in a recent
article titled
"COVID-19 and the Opioid Crisis: Dueling Epidemics
Illustrate the Need for Future Action" that was written
by Lauren
Biscaldi and published April 15, 2021 in Neurology
Advisor. (https://www.neurologyadvisor.com/topics/pain/two-concurrent-health-emergencies-covid-19-and-the-opioid-crisis/)
Leveraging
the
Company's drug free,
non-invasive,
non-toxic method to treat pain, Electromedical Technologies
has seen
strong sales of its current
bioelectronics
device
and upon FDA
clearance, is positioned to increase its market share via its mass
market-designed WellnessPro
POD™.
Matthew Wolfson,
Founder and CEO of Electromedical Technologies ,
Inc (OTCQB:
EMED), noted,
"We have the ability to help
people live pain free and are pleased that the Company has
entered this critical accelerated
phase of
the development
process for our
new bioelectronics
device
that will be
geared toward retail mass market. We understand that with
COVID-19 and the overall opioid crisis in
general,
there is a strong
need to help patients suffering from chronic and acute pain without
causing addiction. We truly believe that our Company's products,
especially a retail version, will position EMED to be the go-to
safe, non
invasive drug free choice
to opioids and
allow us to enter into a whole new market. Bioelectronics is the future
of medicine and this is why major companies like
Google,
GSK and other top pharmaceutical companies
are investing heavily into this space!"
About Electromedical Technologies
Headquartered in
Scottsdale, Arizona, Electromedical
Technologies, Inc. is a commercial stage, FDA cleared,
bioelectronic medical device manufacturing company initially
focused on the treatment of various chronic, acute, intractable,
and post-operative pain conditions. Through University collaboration
agreements, the Company is working to develop
a comprehensive research program in defining the effects of
electro-modulation on the human body. By studying the impacts of
electrical fields in cell signaling and immune
responses,
the Company's goal is to reduce pain and
improve overall human wellbeing. The
Company's current
FDA
cleared product
indications are for chronic acute post traumatic and
post-operative, intractable pain relief. For more information,
please
visit
www.electromedtech.com.
Safe Harbor Statement
This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about
future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which
they are based are reasonable, we can give no assurance or
guarantee that such expectations and assumptions will prove to have
been correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," or
"project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to: adverse economic conditions,
competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate
capital, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
other specific risks. To the extent that statements in this press
release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Hanover
International
Tel:
1.888.880.7888
email:
ir@electromedtech.com
https://electromedtech.com
ElectroMedical Technolog... (PK) (USOTC:EMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
ElectroMedical Technolog... (PK) (USOTC:EMED)
Historical Stock Chart
From Apr 2023 to Apr 2024